Whole blood viscosity and arterial thrombotic events in patients with systemic lupus erythematosus

Arthritis Care and Research

Volumn 57, Issue 5, 2007, Pages 845-850

  Booth, Stephanie ^a   Chohan, Saima ^b   Curran, James C ^b   Karrison, Theodore ^b   Schmitz, Amanda ^b   Utset, Tammy O ^b  

^a Seton Health Systems   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cardiovascular; Lupus; Rheology

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; GLUCOCORTICOID; HEPARIN; PHOSPHOLIPID ANTIBODY; PREDNISONE; WARFARIN;

ADULT; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; ATHEROGENESIS; BLOOD VISCOSITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; SHEAR RATE; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; VEIN THROMBOSIS;

ADULT; BLOOD VISCOSITY; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; RHEOLOGY; RISK FACTORS; THROMBOSIS;

EID: 34250690360     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.22766     Document Type: Article

References (42)

1. Mok CC, Tang SS, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 2005;52: 2774-82.
2. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408-15.
3. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331-7.
4. Bessant R, Hingorani A, Patel L, MacGregor A, Isenberg DA, Rahman A. Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford) 2004;43:924-9.
5. Krishnan E. Stroke subtypes among young patients with systemic lupus erythematosus. Am J Med 2005;118:1415e1-7.
6. Bruce IN, Urowitz MB, Gladman DD, Ibanez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 2003;48:3159-67.
7. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus [published erratum appears in N Engl J Med 2006;355:1746]. N Engl J Med 2003;349:2399-406.
8. Svenungsson E, Jensen-Urstad K, Heimburger M, Silveira A, Hamsten A, de Faire U, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104:1887-93.
9. Woodward M, Rumley A, Tunstall-Pedoe H, Lowe GD. Does sticky blood predict a sticky end? Associations of blood viscosity, haematocrit and fibrinogen with mortality in the West of Scotland. Br J Haematol 2003;122:645-50.
10. Woodward M, Rumley A, Lowe GD, Tunstall-Pedoe H. C-reactive protein: associations with haematological variables, cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 2003;122:135-41.
11. Smith FB, Rumley A, Lee AJ, Leng GC, Fowkes FG, Lowe GD. Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants. Br J Haematol 1998;100:758-63.
12. Lowe GD, Lee AJ, Rumley A, Price JF, Fowkes FG. Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br J Haematol 1997;96:168-73.
13. Danesh J, Collins R, Peto R, Lowe GD. Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J 2000;21:515-20.
14. De Backer TL, de Buyzere M, Segers P, Carlier S, de Sutter J, van de Wiele C, et al. The role of whole blood viscosity in premature coronary artery disease in women. Atherosclerosis 2002;165:367-73.
15. Ciuffetti G, Schillaci G, Lombardini R, Pirro M, Vaudo G, Mannarino E. Prognostic impact of low-shear whole blood viscosity in hypertensive men. Eur J Clin Invest 2005;35: 93-8.
16. Kensey KR. The mechanistic relationships between hemorheological characteristics and cardiovascular disease. Curr Med Res Opin 2003;19:587-96.
17. Negrean V, Suciu I, Sampelean D, Cozma A. Rheological changes in diabetic microangiopathy. Rom J Intern Med 2004; 42:407-13.
18. Cicco G, Pirrelli A. Red blood cell (RBC) deformability, RBC aggregability and tissue oxygenation in hypertension. Clin Hemorheol Microcirc 1999;21:169-77.
19. Brown CD, Ghali HS, Zhao Z, Thomas LL, Friedman EA. Association of reduced red blood cell deformability and diabetic nephropathy. Kidney Int 2005;67:295-300.
20. Lowe GD. Blood rheology in vitro and in vivo. Baillieres Clin Haematol 1987;1:597-636.
21. Alexy T, Wenby RB, Pais E, Goldstein LJ, Hogenauer W, Meiselman HJ. An automated tube-type blood viscometer: validation studies. Biorheology 2005;42:237-47.
22. Wang S, Boss AH, Kensey KR, Rosenson RS. Variations of whole blood viscosity using Rheolog: a new scanning capillary viscometer. Clin Chim Acta 2003;332:79-82.
23. Grondal G, Gunnarsson I, Ronnelid J, Rogberg S, Klareskog L, Lundberg I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 2000;18:565-70.
24. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus: a putative role in pathogenesis. J Immunol 1991;147:117-23.
25. Peterson E, Robertson AD, Emlen W. Serum and urinary interleukin-6 in systemic lupus erythematosus. Lupus 1996;5: 571-5.
26. Woodward M, Rumley A, Tunstall-Pedoe H, Lowe GD. Associations of blood rheology and interleukin-6 with cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 1999;104:246-57.
27. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000;148:209-14.
28. Ernst E, Hein A, Meurer M, Ruzicka T. Blood rheology in lupus erythematosus. Ann Rheum Dis 1991;50:710-2.
29. Reid HL, de Ceulaer K. Abnormal plasma and serum viscosity in systemic lupus erythematosus (SLE): a Jamaican study. Clin Hemorheol Microcirc 1999;20:175-80.
30. Rosenson RS, Shott S, Katz R. Elevated blood viscosity in systemic lupus erythematosus. Semin Arthritis Rheum 2001; 31:52-7.
31. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
32. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309-11.
33. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
34. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2407-15.
35. Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Pratt JE, Tracy RP, Kuller LH, et al. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum 2004;50:151-9.
36. Alt E, Banyai S, Banyai M, Koppensteiner R. Blood rheology in deep venous thrombosis: relation to persistent and transient risk factors. Thromb Res 2002;107:101-7.
37. Lowe G, Rumley A, Norrie J, Ford I, Shepherd J, Cobbe S, et al. Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study [published erratum appears in Thromb Haemost 2001;85: 946]. Thromb Haemost 2000;84:553-8.
38. Szapary L, Horvath B, Marton Z, Alexy T, Kesmarky G, Habon T, et al. Short-term effect of low-dose atorvastatin on haemorrheological parameters, platelet aggregation and endothelial function in patients with cerebrovascular disease and hyperlipidaemia. CNS Drugs 2004;18:165-72.
39. McCarty MF. Favorable impact of a vegan diet with exercise on hemorheology: implications for control of diabetic neuropathy. Med Hypotheses 2002;58:476-86.
40. Solerte SB, Fioravanti M, Cerutti N, Severgnini S, Locatelli M, Pezza N, et al. Retrospective analysis of long-term hemorheologic effects of pentoxifylline in diabetic patients with angiopathic complications. Acta Diabetol 1997;34:67-74.
41. Dawson DL, Zheng Q, Worthy SA, Charles B, Bradley DV Jr. Failure of pentoxifylline or cilostazol to improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in claudication. Angiology 2002;53:509-20.
42. Bacher A, Eggensperger E, Koppensteiner R, Mayer N, Klimscha W. Pentoxifylline attenuates the increase in whole blood viscosity after transfusion. Acta Anaesthesiol Scand 2005;49: 41-6.